| Period | Revenue ($M) |
|---|---|
| 2024 | $1,800M |
| 2025 | $2,200M |
| Indication | Stage | Key Study | Regional Status |
|---|---|---|---|
| Schizophrenia | APPROVED | Phase 3 (BEACON/Vector) | [{"stage":"APPROVED","region":"US","approval_date":"2015-07-10"},{"stage":"APPRO |
| MDD adjunctive | APPROVED | Pyxis/Polaris | [{"stage":"APPROVED","region":"US","approval_date":"2015-07-10"}] |
| Alzheimer's agitation | APPROVED | Phase 3 (Study 331-14-213) | [{"stage":"APPROVED","region":"US","approval_date":"2023-05-11"},{"stage":"APPRO |
| PTSD | PHASE3 | Phase 3 PTSD studies | [] |